Jetzt bei Österreichs bestem Online Broker Depot eröffnen!-w-
16.05.2018 20:57:00

IQVIA Response to FDA Statement

IQVIA™ (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. We also provide a select set of services to the FDA and other government agencies. Recently, we made a correction to a kilogram conversion measurement in the United States IQVIA National Sales Perspective (NSP) market research service affecting reported measurements for transdermal patches in the opioid market. This kilogram measurement is reported in the NSP market research service. This measurement conversion issue does not impact our widely used US and global dollar and unit information in NSP or information in any other IQVIA market research services, methodologies or offerings.

IQVIA’s internal processes had already identified the measurement conversion issue prior to the FDA’s notification. We notified our clients about this measurement conversion issue in April of this year. Ongoing steps have been undertaken to correct this measurement conversion issue in this offering.

We stand behind our data methodologies. We value our long-standing relationship with the FDA. We take the FDA’s concerns seriously and will continue working with the FDA to resolve these concerns to its satisfaction.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation, and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.IQVIA.com.

Click here to subscribe to Mobile Alerts for IQVIA.

Analysen zu Quintiles Transnational Holdings INCmehr Analysen

27.10.17 Quintiles Transnational overweight Barclays Capital
27.10.17 Quintiles Transnational Buy Stifel, Nicolaus & Co., Inc.
19.09.17 Quintiles Transnational Outperform RBC Capital Markets
07.07.17 Quintiles Transnational Neutral Robert W. Baird & Co. Incorporated
04.05.17 Quintiles Transnational Buy Mizuho

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
pagehit